SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

C L I N I C A L O N C O L O G Y R E S E A R C H P R O G R A M
fusion protein targeting to xenogeneic (e.g., CEA,
her2/neu) antigens, while preserving T-cell
immune-effector functions. The B-cell deficient
model also has demonstrated T-cell responses to
tumor and may be better than those seen in the
immunocompetent mouse. The laboratory is
currently investigating the reasons for altered
responses in the absence of B cells, and the possibility
of applying this approach to clinically using
antibody depletion of B cells with rituximab.
Dr. Rosenblatt and his colleagues also have
collaborated with the laboratory of Vicente
Planelles, Ph.D., at the University of Utah, on
developing several new approaches to HIV-1 gene
therapy. These include the use of mutated tRNA LYS3
primers, which can anneal to the sequences other
than primer-binding sequences on the HIV-1
genome, or tRNA LYS3 mutated in adenosine residue
A58, which prevents normal methylation of
the adenosine residue and disrupts proper termination
of the nascent reverse transcript, thereby
inhibiting completion of HIV-1 reverse transcription
in model systems. Other investigations have
centered on the effects of defective HIV-1 derived
vectors on HIV-1 spread in culture. Recent experiments
have demonstrated that efficient trafficking
of defective HIV-1 vectors is observed
in vitro following superinfection with wild type
HIV-1 and that such trafficking results in a
marked inhibition of wild type viral spread.
SELECTED PUBLICATIONS
2002
Lancet, JE, Rosenblatt, JD , and Karp, JE.
Farnesyltransferase inhibitors and myeloid malignancies:
phase I evidence of Zarnestra activity in
high-risk leukemias. Seminars in Hematology
39:31-35, 2002.
Tolba, KA, Bowers, WJ, Muller, J, Housekneckt,
V, Giuliano, RE, Federoff, HJ, and Rosenblatt,
JD. Herpes simplex virus (HSV) amplicon-mediated
codelivery of secondary lymphoid tissue
chemokine and CD40L results in augmented antitumor
activity. Cancer Research 62:6545-51,
2002.
Rosenblatt, JD , Shin, SU, Nechustan, H, Yi,
KH, and Tolba, K. Potential role of chemokines
in immune therapy of cancer. Israel Medical Association
Journal 4:1054-59, 2002.
Tolba, KA, Bowers, WJ, Eling, DJ, Casey, AE,
Kipps, TJ, Federoff, HJ, and Rosenblatt, JD .
HSV amplicon-mediated delivery of LIGHT enhances
the antigen-presenting capacity of chronic
lymphocytic leukemia. Molecular Therapy 6:455-
63, 2002.
Andela, VB, Rosenblatt, JD , Schwarz, EM,
Puzas, EJ, O’Keefe, RJ, and Rosier, RN. Synergism
of aminobisphosphonates and farnesyl
transferase inhibitors on tumor metastasis. Clinical
Orthopaedics 397:228-39, 2002.
2003
Khorana, AA, Rosenblatt, JD , Sahasrabudhe,
DM, Evans, T, Ladrigan, M, Marquis, D, Rosell,
K, Whiteside, T, Phillippe, S, Acres, B, Slos, P,
Squiban, P, Ross, M, and Kendra, K. A phase I
trial of immunotherapy with intratumoral adenovirus-interferon-gamma
(TG1041) in patients
with malignant melanoma. Cancer Gene Therapy
10:251-9, 2003.
Andela, VB, Pirri, M, Schwarz, EM, Puzas, EJ,
O’Keefe, RJ, Rosenblatt, JD, and Rosier, RN.
The mevalonate synthesis pathway as a therapeutic
target in cancer. (Review) Clinical Orthopaedics
415 (Supplement):S59-66, 2003.
Liesveld, JL, Lancet, JE, Rosell, KE, Menon, A,
Lu, C, McNair, C, Abboud, CN, and Rosenblatt,
JD. Effects of the farnesyl transferase inhibitor
R115777 on normal and leukemic hematopoiesis.
Leukemia 17:1806-12, 2003.
Rosenblatt, JD and Harrington, WJ Jr. Leukemia
and myelopathy: the persistent mystery of pathogenesis
by HTLV-I/II. Cancer Investigation
21:323-24, 2003.
UM/Sylvester Comprehensive Cancer Center Scientific Report 2004 55